Recent reports have demonstrated that miR-29 acts as a downstream inhibitor and therapeutic miR for TGF-β1/Smad3- mediated renal fibrosis [26] and myogenic differentiation [27]. The gene discussed is TGFB1; the disease is renal fibrosis.